Literature DB >> 26585412

Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group.

D A Eichenauer1,2, H Goergen1,2, A Plütschow1,2, D Wongso2, K Behringer1,2, S Kreissl1,2, I Thielen2, T Halbsguth2, P J Bröckelmann1,2, M Fuchs1,2, B Böll1,2, B von Tresckow1,2, P Borchmann1,2, A Engert1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26585412     DOI： 10.1038/leu.2015.321

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

Review 1.  VII. Management of nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Dennis A Eichenauer; Andreas Engert
Journal:  Hematol Oncol       Date:  2013-06       Impact factor: 5.271

2.  Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Authors:  Dennis A Eichenauer; Michael Fuchs; Annette Pluetschow; Beate Klimm; Teresa Halbsguth; Boris Böll; Bastian von Tresckow; Lucia Nogová; Peter Borchmann; Andreas Engert
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

3.  A simplified scoring system to document variant patterns in nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  Tanuja Shet; Poonam Panjwani; Sridhar Epari; Manju Sengar; Maya Prasad; Brijesh Arora; Siddhartha Laskar; Sumeet Gujral; Hari Menon; Shripad Banavali
Journal:  Leuk Lymphoma       Date:  2014-11-20

4.  Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.

Authors:  Irene Biasoli; Aspasia Stamatoullas; Véronique Meignin; Alain Delmer; Oumedaly Reman; Franck Morschhauser; Bertrand Coiffier; André Bosly; Marine Diviné; Pauline Brice
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

5.  Hodgkin lymphoma, version 2.2015.

Authors:  Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Celeste M Bello; Cecil M Benitez; Philip J Bierman; Kristie A Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; Jiayi Huang; Patrick B Johnston; Nadia Khan; David G Maloney; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Christina Tsien; Jane N Winter; Joachim Yahalom; Jennifer L Burns; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

6.  Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.

Authors:  Martin T King; Sarah S Donaldson; Michael P Link; Yasodha Natkunam; Ranjana H Advani; Richard T Hoppe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-01       Impact factor: 7.038

7.  Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Ranjana H Advani; Sandra J Horning; Richard T Hoppe; Sarah Daadi; John Allen; Yasodha Natkunam; Nancy L Bartlett
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

8.  High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Meghan Karuturi; Chitra Hosing; Michelle Fanale; L Jeffrey Medeiros; Amin M Alousi; Marcos J de Lima; Muzaffar H Qazilbash; Partow Kebriaei; Anas Younes; Issa Khouri; Borje S Andersson; Richard Champlin; Paolo Anderlini; Uday Popat
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-16       Impact factor: 5.742

9.  Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.

Authors:  Mubarak Al-Mansour; Joseph M Connors; Randy D Gascoyne; Brian Skinnider; Kerry J Savage
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

10.  Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

Authors:  Holger Schulz; Ute Rehwald; Franck Morschhauser; Thomas Elter; Christoph Driessen; Thomas Rüdiger; Peter Borchmann; Roland Schnell; Volker Diehl; Andreas Engert; Marcel Reiser
Journal:  Blood       Date:  2007-10-15       Impact factor: 22.113
View more
  4 in total

Review 1.  An Update on the Use of Immunotherapy in the Treatment of Lymphoma.

Authors:  Thomas U Marron; Matko Kalac; Joshua Brody
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

Review 2.  Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.

Authors:  Dennis A Eichenauer; Andreas Engert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Chelsea C Pinnix; Sarah A Milgrom; Chan Yoon Cheah; Jillian R Gunther; Ethan B Ludmir; Christine F Wogan; Loretta J Nastoupil; Sattva S Neelapu; Jason Westin; Hun J Lee; Swaminathan P Iyer; Raphael E Steiner; Luis E Fayad; Nathan H Fowler; Michael L Wang; Felipe Samaniego; Maria A Rodriguez; Amy E Rich; L Jeffrey Medeiros; Bouthaina S Dabaja
Journal:  Blood Adv       Date:  2019-05-14

4.  Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Sven Borchmann; Erel Joffe; Craig H Moskowitz; Andrew D Zelenetz; Ariela Noy; Carol S Portlock; John F Gerecitano; Connie L Batlevi; Philip C Caron; Pamela Drullinsky; Audrey Hamilton; Paul A Hamlin; Steven M Horwitz; Anita Kumar; Matthew J Matasar; Alison J Moskowitz; Colette N Owens; M Lia Palomba; Anas Younes; David J Straus
Journal:  Blood       Date:  2019-02-15       Impact factor: 22.113
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.